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ABSTRACT 
Photochemical Delivery of Bleomycin 
in Malignant Glioma Cells 
by 
Joseph William Blickenstaff III 
Dr. Steen Madsen, Examination Committee Chair 
Professor of Health Physics 
University of Nevada, Las Vegas 
Despite continued efforts, glioblastoma multiforme (GBM) remains an incurable form 
of primary brain cancer. Surgical resection followed by radiation treatment and 
chemotherapy have been the most effective modalities in prolonging median survival 
time to 14 months. This research aims to study the response of two different cell culture 
models to a novel drug delivery method termed photochemical internalization (PCI). PCI 
is a technique to improve the utilization of macromolecules (e.g. the chemotherapeutic 
drug bleomycin) in site-specific cancer therapy. This concept is based on the use of 
specially designed photosensitizers (e.g. aluminum phthalocyanine disulfonate; AlPcS2a) 
which preferentially localize in the membranes of endocytic vesicles. 
The utility of PCI for treating malignant gliomas was investigated in vitro using: (1) 
F98 rat glioma monolayer cells, and (2) biopsy-derived human glioma spheroids. For 
both in vitro systems, PCI was found to interact in a synergistic manner resulting in 
significant toxicity. For example, the combination of 1.5 J/cm2 photodynamic therapy 
(PDT) and 0.25 (xg/mL bleomycin resulted in approximately 25% survival in F98 rat 
glioma cells while only 35% of human glioma spheroids were observed to be growing 
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two weeks post treatment. Overall, the degree of synergism was found to be less 
pronounced in the spheroid model. Collectively, the results show that AlPcS2a-mediated 
PCI can be used to enhance the efficacy of chemotherapeutic agents such as bleomycin in 
malignant gliomas. 
IV 
TABLE OF CONTENTS 
ABSTRACT iii 
LIST OF FIGURES vii 
ACKNOWLEDGMENTS viii 
CHAPTER 1 INTRODUCTION: 1 
1.1 Malignant glioma 1 
1.2 F98 monolayer 6 
1.3 Multicellular tumor spheroids 8 
1.4 Bleomycin 16 
1.5 Aluminum phthalocyanine disulfonate 20 
1.6 Photodynamic therapy (PDT) 23 
1.7 Photochemical internalization (PCI) 31 
1.8 Scope of study
 r 33 
CHAPTER 2 MATERIALS AND METHODS 34 
2.1 Cell lines 34 
2.2 Monolayer survival plating 36 
2.3 Spheroid growth analysis 37 
2.4 Bleomycin toxicity 38 
2.5 PDT toxicity 38 
2.6 PCI toxicity 39 
2.7 Flow cytometry 39 
2.8 Two-photon fluorescence microscopy (TPFM) , 40 
2.9 Statistical analysis 41 
CHAPTER 3 RESULTS 43 
3.1 AlPcS2a and bleomycin toxicity in F98 monolayer 43 
3.2 PDT toxicity in F98 monolayer 45 
3.3 PCI toxicity in F98 monolayer 46 
3.4 ACBT spheroid growth assays 49 
3.5 Determination of spheroid cell viability by flow cytometry 54 
3.6 Two-photon fluorescence microscopy 55 
CHAPTER 4 CONCLUSIONS 57 
APPENDICES 60 
v 
APPENDIX I ACBT spheroid growth assay p-values 60 
APPENDIX II Flow cytometry raw data 61 
REFERENCES 74 
VITA 80 
VI 
LIST OF FIGURES 
Figure 1 Primary brain tumor distribution by histology 1 
Figure 2 Primary brain and CNS glioma distribution by histology 3 
Figure 3 Monolayer of normal glial cells 7 
Figure 4 Monolayer of F98 rat glioma cells 8 
Figure 5 Human colon adenocarcinoma spheroid 11 
Figure 6 Solid tumor and MTS growth curve 12 
Figure 7 Structure of bleomycin and its analogues 16 
Figure 8 Structure of AlPcS2a 21 
Figure 9 PDT action mechanism 28 
Figure 10 Jablonski diagram for photoactivation of singlet oxygen 28 
Figure 11 Optical window in tissue 29 
Figure 12 PCI diagram 32 
Figure 13 Percent survival vs. AlPcS2a concentration for F98 monolayers 44 
Figure 14 Percent survival vs. bleomycin concentration for F98 monolayers 44 
Figure 15 Percent survival vs. PDT treatments 46 
Figure 16 Percent survival vs. various treatments 48 
Figure 17 Average spheroid diameter vs. days post-treatment 51 
Figure 18 Average spheroid diameter vs. days post-treatment (first 8 days) 52 
Figure 19 Percentage of spheroids viable for weeks 1 through 4 53 
Figure 20 Flow cytometry results for percent composition 55 
Figure 21 TPFM images of ACBT spheroids 48 hours post-treatment 56 
vii 
ACKNOWLEDGMENTS 
This research project would not have been realized without the gracious support of so 
many people. I would first like to thank my advisor, Dr. Steen Madsen, his assiduous 
support and exceptional guidance throughout have been invaluable. 
I wish to extend my thanks to the thesis committee members Dr. Phillip Patton, Dr. 
Ralf Sudowe, and Dr. Mack Rubley whose knowledge and excellent assistance ensured 
the success of this project. 
Special thanks are also in order for the wonderful support of Van Vo, Mary Turner, 
and Doris Coomes during the course of my research and studies at UNLV. 
I would finally like to express my gratitude to all my friends and family. Thank you, 
Emily, for all your encouragement and support over the years. I dedicate this work to my 
mother and father, for showing me the right paths and never letting me doubt that I could 
take them. 
vm 
CHAPTER 1 
INTRODUCTION 
1.1 Malignant glioma 
While primary malignant brain tumors account for only 2% of all cancer cases in the 
United States, their prognoses are among the worst as they also account for 2% of all 
cancer related deaths each year (Chandana et al. 2008; Newton 2008). Brain tumors are 
classified, according to the World Health Organization (WHO), by cellular origin and 
histologic appearance. For all primary brain tumors, the Central Brain Tumor Registry of 
the United States (CBTRUS) compiles incidence statistics by histology (Fig. 1). 
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Figure 1. Primary brain and CNS tumor distribution by histology; collected 2000-
2004 (n=73,583). (Adapted from CBTRUS 2008) 
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All primary brain tumors present with similar symptoms, regardless of histology. Some 
of these symptoms include (in decreasing occurrence rate): headache, memory loss, 
seizures, personality change, visual problems, nausea or vomiting (Chananda et al. 2008). 
The locations of headaches and severity of other symptoms can aid in diagnosis. A 
cranial magnetic resonance imaging (MRI) scan with gadolinium contrast is typically all 
that is necessary to diagnose a primary brain tumor. However, computed tomography 
(CT) can also be used to better localize and measure the tumor's dimensions. CBTRUS 
reports an age-adjusted incidence for primary brain tumors to be 6.45 in 100,000 people 
per year (CBTRUS 2008). This figure has increased in recent years, yet numerous 
studies have failed to connect most environmental factors to an increased risk of brain 
tumor development. Factors such as electromagnetic fields, pesticides, cellular phones, 
head trauma, and N-nitroso compounds have all been studied with inconclusive results. 
Increased exposure to ionizing radiation is the only proven factor to increase risk. Even 
low doses have been shown to increase incidence of meningiomas by a factor of 10 and 
glial tumors by a factor of 3-7. The latency period for such occurrences is 10-20 years 
after being exposed (DeAngelis 2001). The median survival depends significantly on the 
histology and malignancy of the tumor, but there are factors that show a favorable 
prognosis for patients. These factors include: patients younger than 60 years, patients 
presenting with seizures, tumor located in the frontal lobe, absence of tumor necrosis, and 
total or near-total bulk resection (Chandana et al. 2008). Primary brain tumors rarely 
metastasize outside the central nervous system (CNS) leading to no real standard of 
staging. 
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Gliomas comprise the vast majority of malignant brain tumors, and still remain 
incurable. Gliomas account for 36% all primary brain tumors and 81% of malignant 
tumors (CBTRUS 2008). Symptoms are similar to those of other primary brain tumors 
with headaches occurring in 50% of patients. In malignant gliomas, seizures are less 
prevalent occurring in only 15-25%, while mental-state abnormalities in general occur in 
40-60% of all patients. Gliomas can be pathologically graded according to the presence 
or absence of nuclear atypia, mitosis, microvascular proliferation and necrosis 
(DeAngelis 2001). Grades I and II tumors are both low-grade (i.e. and grades III and IV 
are high-grade. Of all malignant gliomas, glioblastoma multiforme (GBM) is the most 
malignant and common comprising (along with other astrocytomas) 75% of all gliomas 
(Fig. 2, CBTRUS 2008). 
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Figure 2. Primary brain and CNS glioma distribution by histology subtypes; collected 
2000-2004 (n=26,630). (Adapted from CBTRUS 2008) 
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GBM is the most common brain tumor in adults and accounts for approximately 40% 
of primary tumors and 80% of high-grade primary CNS neoplasms and is classified as a 
grade IV astrocytoma (Newton 2008). GBM comprises 18.5% of all reported brain 
tumors and affects 3 in every 100,000 people per year with a median age at diagnosis of 
64 years (CBRTUS 2008). GBM growth is characterized as having a high cellular 
motility and a resistance to apoptosis. As with other gliomas, GBMs are heterogeneous 
both histologically and genetically. These factors result in extreme difficulties when 
treating GBMs. Gross GBM tumor pathology is characterized by a central core of 
necrosis surrounded by pseudopalisading cells along with angiogenesis. Typically these 
cells will infiltrate several centimeters or more away from the bulk tumor into the 
surrounding brain (DeAngelis 2001). This infiltration, along with the production of 
glutamate which acts to kill surrounding brain cells, facilitates rapid tumor expansion. 
Furthermore, glioma cells have demonstrated the ability to quickly change shape and 
volume as they move further into surrounding parenchyma (Lefranc 2009). All of this 
leads to GBM being an extremely aggressive and difficult cancer to treat. The median 
survival rate remains only 14.6 months when utilizing the current treatment standard of 
maximum tumor bulk resection followed by radiotherapy and chemotherapy with 
temozolomide (TMZ) (Newton 2008; Lefranc 2009). 
While there have been recent advancements in the treatment of GBM, relative 
survival rates have increased very little. The one, three, five, and ten-year relative 
survival rates for GBM are 29.6, 5.2, 3.4, and 2.4 respectively (CBTRUS 2008). These 
values have improved only slightly compared with data collected over a decade prior. 
The current standard treatment once a patient is diagnosed with GBM begins with a 
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surgical resection of the tumor. This resection, or de-bulking, is performed by 
aggressively removing as much tissue as possible without adversely affecting the patient's 
quality of life. Resection not only removes tumor tissue, but will reduce intracranial 
pressure that leads to many of the common symptoms. 
Following surgery, the patient is typically administered radiotherapy and 
chemotherapy in combination. Radiotherapy is generally given in the form of external 
beam, administered in 2 Gy fractions daily for 30 fractions. A total dose of 60 Gy is 
often followed by a subsequent boost dose. Several chemotherapy options exist, with the 
most recent standard being TMZ. This is typically given in 75 mg/m2 per day for the 6 
weeks during radiotherapy treatment. This is followed by at least 6 cycles of 150-200 
mg/m2 per day for 5 days given every 28 days (Newton 2008). This protocol was shown 
to improve the median survival rate of patients from 12.1 to 14.6 months when compared 
to radiotherapy alone (Chandana et al. 2008; Newton 2008). An increase in two-year 
survival rate from 10.4% to 26.5% was also seen when compared to traditional 
radiotherapy alone. Even more impressive increases in the three and four-year survival 
rates were also observed. The three-year survival rate increased from 4.3% to 16.7% and 
the four-year went from 3.8% to 12.9% (Newton 2008). The survival rates given here by 
Newton (2008) are slightly different than those found in the CBTRUS 2008 Report as 
their pool of data was collected over different time scales. 
Beyond the standard treatment protocol, several alternative medicines are being 
studied. Some of these alternative medicine treatments include: methyl guanine and 
methyl transferase (MGMT) promoter methylation, epidermal growth factor receptor 
(EGFR) inhibitors, antiangiogenics, as well as other growth factor and signal transduction 
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targeted drugs. MGMT has shown some promise, but it, along with the other drugs, is 
still in clinical trials (Chandana 2008; Fadul et al. 2008; Newton 2008). 
The most likely reason for chemotherapy's poor results lies in poor drug transmission 
across the blood-brain barrier. The difficult delivery of some drugs to the CNS as well as 
the genetic differences from one tumor to another has led some to propose genotyping 
each tumor and custom fitting treatments, in order to fit each individual patient's needs. 
This type of individual treatment will unfortunately take many years to develop. It can be 
agreed that while recent advancements have made incremental steps forward, there is a 
dire need to develop new and more effective therapies for GBM (DeAngelis 2001; Fadul 
et al. 2008). 
1.2 F98 monolayer 
F98 is an undifferentiated rat glioma cell line that shares many characteristics with 
human GBMs, and is used in this study to examine all therapeutic effects on monolayer 
configurations. The F98 cell line is morphologically different from normal glial cells, 
which typically form a monolayered configuration similar to that of epithelial cells. Glial 
cells have a polygonal cell body with profuse cytoplasm and a flat nucleus (Fig. 3). The 
nucleus often contains multiple nucleoli, but the amount of cytoplasm present in the cell 
grants it a low nuclear-cytoplasmic ratio. Glial cells typically have long processes that 
are thin and interdigitated with other glial cells at confluence. Normal glial cells have a 
low mitotic index. Ko et al. (1980) measured average glial cell body diameters to be 39.8 
± 5.0 urn Also measured by Ko et al. were the average number of processes (2.6 ± 0.2) 
and process length (114.1 ±11.2 um). Glioma cells are distinctive in the criss-crossed 
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alignment of their processes at confluence, high nuclear-cytoplasmic ratio, and higher 
mitotic index (Fig. 4). F98 cells originate from undifferentiated gliomas and possess a 
high degree of morphological homogeneity. The F98 cell line was characterized by Ko et 
al. to have a cell body diameter of 29.5 ± 2.0 jam, as well as an average number of 4.6 ± 
0.3 processes with a length of 28.5 ± 3.1 urn. The F98 cell line demonstrated a high 
morphological stability and retained its distinctive characteristics throughout multiple in 
vitro propagations. It was concluded that this stability, growth, and morphology would 
make F98 an excellent model system for studying therapeutic effects (Ko et al. 1980). 
Figure 3. Monolayer of normal rat glial cells. Arrows indicate mitotic figure in early 
telophase (Koetal. 1980). 
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Figure 4. Monolayer of F98 rat glioma cells. Arrows indicate mitoses (Ko et al. 1980). 
F98 glioma cells are specifically applicable for this study, because they share many 
characteristics of in vivo growth with human GBM cells (Madsen et al. 2007). When 
used to induce tumors in Fisher rats, F98 tumors exhibit rapid growth, infiltrative 
behavior, extensive neovascularization, and absence of encapsulation (Barth RF 1998). 
F98 cell cultures will be used to study several therapeutic effects in a monolayer cell 
model. 
1.3 Multicellular tumor spheroids 
While monolayer cell cultures such as F98 have proven to be well established for use 
in biomedical experiments, there are limitations in utilizing these two-dimensional in 
vitro models. Monolayer cell cultures allow for a well-controlled cellular environment 
that is easy to analyze in comparison to in vivo studies. Experiments performed in vivo 
better replicate the cellular environment, but are much more complex, costly, and 
unpredictable. Thus arose the need for a middle ground between control and complexity. 
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Multicellular tumor spheroids (MTS) are not new to the field of biomedical research. 
They have been in use since the 1940s and 1950s when Holtfreder and Moscona 
separately worked on using these spheroidal aggregates of cells to study embryonic and 
malignant cells (Mueller-Klieser 2000). It was, however, Robert M. Sutherland and 
others that pioneered the use of MTS in cancer research beginning in the 1970s. The 
bulk of Sutherland's research revolved around the response of MTS to therapy. Most of 
the initial work focused on ionizing radiation therapies. Since then, MTS have been 
widely used to investigate various biological mechanisms and specific cellular responses 
to a broad range of therapeutic techniques. Their well organized morphology 
incorporates cell-cell interactions including gene and growth factor expressions, as well 
as oxygen and nutrient gradients (Kim 2005). Not all cell lines are able to form MTS, but 
several techniques have made it possible for many cell types to bridge that experimental 
gap between two-dimensional cell cultures in vitro and tumors in vivo. 
MTS are meant to simulate the characteristics of avascular tumor nodules and 
microregions in vivo. They take advantage of homotypic aggregation, a common 
characteristic of malignant cells. Their natural tendency towards cell-cell adhesion 
allows for this self-propelled growth in vitro. As the spheroids grow in diameter, they 
begin to develop a complex cellular environment, directly applicable to what is found in 
human tumors. Three classes of cells are commonly found in human tumors. The first 
class being that of proliferating cells found on the tumor's perimeter and always near 
ready sources of nutrients and oxygen. These proliferating cells are characterized by 
rapid growth and a high mitotic index. The second class of cells is in a quiescent state 
and these cells are located further away from capillaries and other sources of nutrients 
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that limit growth and division. These cells are still provided sufficient nutrients to 
survive, but have stopped cycling. Further separated from any nutrient and or oxygen 
sources is the third class, the necrotic cells (Venkatasubramanian et al. 2006). 
MTS are ideally suited to mimic this type of cellular organization within tumors. 
MTS are characterized by a viable ring (100-220 um; Sutherland 1988) of proliferating 
cells followed by quiescent cells. The proliferating cells compose the outermost 3-5 cell 
layers (75 um; Sutherland 1988). Once an MTS is of sufficient size (100-600 (xm in 
diameter; Kunz-Schughart 1999) a necrotic core will begin to develop. The size at which 
an MTS will develop this necrotic core varies greatly between cell types. These 
variations are the result of differences in substrate consumption rates, cell packing 
densities, and concentrations of substrate within the medium (Sutherland 1988). 
MTS growth is very similar to that of solid tumors. Tumors begin at the microscopic 
level and undergo avascular growth followed by angiogenesis (Guiot et al. 2003). This 
ensures the tumor's continued expansion and infiltration into the local tissue. The tumor 
can progress to metastasize depending on the type of cancer. In much the same fashion, 
MTS growth can be described to occur in three phases. First, the spheroid will undergo 
an initial exponential growth period (typically up to 200 um in diameter). In this phase, 
several cells have loosely aggregated and all are highly proliferative. Slowly, 
intercellular links, such as gap junctions, form and a more compact spheroid begins to 
appear (Fig. 5). At this point the second phase of MTS growth begins. This phase is 
marked by an increasing accumulation of a second cell layer in which cells are no longer 
proliferating. These quiescent cells act to retard the growth process. The MTS is now 
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increasing linearly and a necrotic core has begun to emerge. This linear growth will 
continue until the MTS asymptotically approaches a maximum size. 
Figure 5. 1400x magnification of a human colon adenocarcinoma spheroid depicting the 
compact shape while still showing individual cells (Santini et al. 1999). 
Proliferative cells still remain on the surface, but only act to replace cells lost through 
necrosis and shedding (Folkman and Hochberg 1973; Mueller-Klieser 1987; Dubessy et 
al. 2000). No matter how preferable the environmental conditions are, the MTS will act 
to self-regulate its size without the addition of angiogenesis that allows human tumors to 
continue to grow (Folkman and Hochberg 1973). The growth curve is illustrated in 
Figure 6. Mathematical analysis by Chignola et al. (2000) was able to forecast the 
growth of both rat and human glioblastoma MTS using a modified Gompertz growth 
equation. Their work showed that MTS growth exhibits both variability and saturation. 
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Variability refers to MTSs of identical cell lines whose kinetics at any time during growth 
will demonstrate different volumes. The same spheroidal volumes will eventually both 
saturate in growth and equal each other (Chignola et al. 2000). This demonstrates that 
given different initial conditions, MTS of identical cell lines should reach similar 
maximum volumes. 
TUMOR 
Figure 6. Illustration of solid tumor and MTS growth curve (Mueller-Klieser 1987). 
One could conclude that while many experiments, both in vitro and in vivo, end 
before maximum volume is attained, this finding would allow the prediction of when that 
maximum volume would have been achieved. This would facilitate the direct 
comparison of growth delays caused by therapeutic effects. MTS maximum growth is 
directly regulated by cell death at the spheroid center. Cell death is believed to be 
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primarily caused by necrosis inside the MTS. The development of this necrotic core is 
poorly understood and most likely depends on a complex set of factors that include 
hypoxia (Mueller-Klieser 2000). It has been shown that maximum volume is positively 
correlated with the thickness of the MTSs viable rim, while not being correlated to: 
species, cell type, monolayer or spheroid growth rates, clonogenic capacity, cell packing 
density (Freyer 1988). Those MTS studied exhibited 50-70% of their maximum volume 
to be central necrosis. The conclusion was that certain products generated during the 
necrotic process acted as cell proliferation inhibitors. It is interesting to note that the 
doubling time of some spheroids has been shown to correlate with the growth rates of 
those tumors from which the MTS are generated and this doubling time is longer than 
that of a monolayer culture from that same tumor (Dubessy et al. 2000). This suggests 
that MTS more closely mimic the heterogeneous environment in human tumors when 
compared to monolayer experiments. 
MTS have several advantages and limitations for use in studying the efficacy of 
therapeutic techniques when compared to monolayer cell cultures. These differences 
manifest primarily through the cell-cell and cell-matrix interactions that an MTS model 
provides. In fact MTS and monolayer should be regarded as two distinct models. The 
different phenotypes of cells within an MTS are arranged in an orderly fashion making 
the correlation between structure and function possible. Cellular organization is possible 
through multiple intercellular membrane contacts such as microprojections, tight 
junctions, and desmosomes. Intercellular communication through gap junctions and the 
production of extracellular matrix are made possible by these contacts (Dubessy et al. 
2000). The very structure of the MTS changes the cells' shapes and cellular environment 
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which affects gene expression and therefore biological behavior (Mueller-Klieser 2000). 
This leads to the primary difference between a two-dimensional and three-dimensional 
cell culture. In MTS, an extensive extracellular matrix (ECM) comprised of proteins and 
polysaccharides is formed. In addition to many proteins and growth factors, the ECM 
contains fibronectin, collagen, laminin, hyaluronate, heparan sulfate, and elastin, all in a 
proteoglycan gel (Carlsson and Nederman 1989; Santini et al. 2000). The ECM and 
proteins responsible for cell adhesion, such as integrin, play a vital role in cell survival, 
growth, and death (Santini et al. 2000). Cell adhesion actually acts to inhibit apoptosis. 
Apoptosis is a complex phenomenon whose role in tumor growth is still being studied. 
Recent findings have shown that contrary to common belief, tumor growth is not solely 
the result of the tumor cell's higher proliferative capacity. It is not simply that tumor 
cells grow and divide quicker than normal cells. In fact, tumor growth is the result of an 
imbalance between the production and loss of cells throughout their cell cycle (Santini et 
al. 2000). Through the loss of apoptotic regulation, tumor cells will proliferate in an 
uncontrolled manner. 
All of these complex interactions are what make MTS ideal for studying tumor 
response to a multitude of treatments. MTS have been show to exhibit a multicellular-
mediated resistance to various chemotherapeutics that was lost when the same cells were 
disaggregated and treated in a monolayer (Mueller-Klieser 2000). Their three-
dimensional structure creates oxygen, nutrient, and pH gradients that result in quiescent 
cells which are more resistant to chemotherapy, ionizing radiation, and photodynamic 
therapy. Quiescent cells possess the ability to repair both potentially lethal damage and 
sublethal damage (Dubessy et al. 2000). For all these reasons, MTS have been suggested 
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as mandatory test models in cancer research (Mueller-Klieser 2000). There are, however, 
several limitations to the use of MTS in modeling treatment efficacies. One of the very 
fundamental issues is that many of the unique properties that allow MTS to replicate 
characteristics of solid tumors are poorly understood. These properties include the 
formation of a necrotic core, apoptotic suppression, in addition to the effects of cell 
adhesion, ECM, and epidermal growth factors affect cell viability. The ECM in MTS is 
actually different from that of tumors in vivo since it is of tumor cell origin as opposed to 
being produced from the surrounding tissue stroma. This will change the gene 
expressions within the ECM (Kim 2005). 
All of these are important distinctions from monolayer cell cultures; which are easier, 
more inexpensive, and faster to work with. Monolayer cells are also grown in conditions 
of optimal growth and re-oxygenation which can be useful in describing a cell line's 
specific characteristics. Monolayer cell cultures do lack gradients and are not very 
representative of actual tumor response to treatment. Normal epithelial cells grown as 
monolayer have demonstrated highly plastic characteristics and actually mimicked 
certain traits of tumor cells in vivo (Kim 2005). The final limitation of MTS is their 
variability with respect to growth which results from a sensitivity to environmental 
conditions. MTS of identical genotype within the same culture have demonstrated a 
coefficient of variance of up to 10% despite efforts to normalize all spheroids to the same 
size (Mueller-Klieser 2000). Freyer and Sutherland also found that fluctuations in 
oxygen or glucose concentrations within their culture medium caused large changes in 
the MTS growth rates and extent of central necrosis (Freyer and Sutherland 1986). 
Human glioma spheroids have shown a large variance in hypoxic markers bound next to 
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the necrotic core suggesting that oxygen levels are not necessarily static and predictable 
once necrosis has formed (Mueller-Klieser 2000). It can become very difficult to monitor 
all these parameters and thus growth rate variations should be expected. 
While the MTS model does have its limitations, the ability to better mimic the tumor 
microenvironment far outweighs these disadvantages. MTS have been shown to be a 
crucial link between monolayer in vitro culturing and tumor work in vivo. MTS are 
particularly useful when studying resistance to ionizing radiation, photodynamic, and 
drug therapies. 
1.4 Bleomycin 
The drug under investigation for this research is a chemotherapeutic called bleomycin 
(BLM) (Fig. 7). Bleomycin is a glycopeptic antibiotic whose molecular weight is 1.5 
kDa. It was discovered by Umezawa et al. in 1966 and is cytotoxic to eukaryotic cells 
due to its ability to bind to and degrade DNA (Stubbe and Kozarich 1987). 
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Figure 7. The structure of bleomycin (Stubbe and Kozarich 1987). 
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The bleomycin molecule has a large hydrophilic structure comprised of four parts: a 
terminal amine, bithiazole, pseudopeptidic, and glycannic (Mir et al. 1996). The terminal 
amine group interacts with nucleic acids. The bithiazole part binds to DNA and interacts 
with the DNA minor groove. Binding to transition metals and DNA sequence 
recognition are performed by the pseudopeptidic part. The final, glycannic, part's 
function is still unknown. Bleomycin forms metal oxide complexes by both binding to 
__ O-J- 0-4- _~ 0-4- 0-f- 0 I 
oxygen as well as redox-active transition metal ions Fe , Co , Zn , Ni , and CuZT 
(Stubbe and Kozarich 1987). Bleomycin requires the presence of oxygen in order to 
initiate DNA breaks. Bleomycin has limited ability to penetrate the cell membrane and is 
found to accumulate in endocytic vesicles. Therefore, bleomycin typically enters the cell 
through receptor-mediated endocytosis by binding to a 250 kDa receptor on the 
membrane (Berg et al. 2005). Once inside the cytosol, bleomycin is a very potent drug, 
however, it must diffuse to the nucleus in order to interact with DNA. 
Bleomycin is typically used as a chemotherapeutic for the treatment of squamous cell 
carcinomas of the head and neck, esophagus, bronchus, and skin, as well as testicular 
cancer and Hodgkin's and non-Hodgkin's lymphoma (Mir et al. 1996; Berg et al. 2005). 
Side effects include pneumonitis (occurs in 46% of patients) and lung fibrosis (occurs in 
3%) which can present after a total cumulative dose of 300 mg BLM/m2 (Mir et al. 1996). 
Patients are typically treated two to three times per week or given a continuous low dose 
for several days. The drug has a biological half-life in blood of 2-4 hours after 
intravenous injection, with 70% excreted after the first 24 hours (Mir et al. 1996). Renal 
excretion is the primary mode of clearance from the body. Wolff et al. (1999) performed 
a meta-analysis on over a thousand articles in order to summarize LC50 (drug 
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concentration required to kill 50% of the cells treated) values for several 
chemotherapeutic drugs. All the data were taken for the treatment of glioma cells and 
bleomycin was found to have an LC50 value of 18.6 mg/L. 
Once bleomycin has entered the cell through an endosome, it faces several barriers to 
its final target, the nucleus. The first barrier is degradation by hydrolytic enzymes, of late 
endosomes and lysosomes. The protein, bleomycin hydrolase, is believed to inactivate 
bleomycin by catalytically deaminating the molecule. The exact location and role of 
bleomycin hydrolase is not well understood, but its function has been demonstrated (Mir 
et al. 1996). Furthermore, bleomycin resistance proteins (BRP) have been shown to 
inactivate bleomycin by forming a stable complex with it and preventing the molecule 
from reaching DNA. BRP are a group of binding proteins with a high specificity for 
bleomycin. These proteins are found in the microorganisms that produce bleomycin and 
bleomycin derivatives. It is no surprise that with all these barriers only 0.1% of the 
bleomycin added to a medium will make it inside the cells (Roy and Horwitz 1984). If 
bleomycin were able to therapeutically bypass these barriers, then its true potency could 
be realized. 
Bleomycin cytotoxicity lies in its ability to create single- and double-strand breaks in 
DNA and other nucleic acids. In this way, bleomycin has a very similar effect to that of 
ionizing radiation damage. Bleomycin's cytotoxic effect does vary between different 
tumor genotypes and is affected by interactions with the cellular membrane, the cell's 
ability for DNA repair, bleomycin hydrolase activity, the cellular uptake mechanisms, 
and the rate of bleomycin efflux (Berg et al. 2005). DNA cleavage occurs at the GC base 
pairs. Bleomycin is secured onto the DNA by the bithiazole and terminal amine parts and 
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often produces two breaks, one each on opposite strands of the DNA. Bleomycin could 
be considered a miniendonuclease because one molecule can produce 8-10 DNA breaks. 
There's also one double-strand break for every 6-8 single-strand breaks on average 
(Povirk et al. 1977). Bleomycin is known to cleave the DNA linker between two 
consecutive nucleosomes, telomere synthetic sequences, and RNAs. This extensive 
chromosome fragmentation does lead to some genotoxic effects. Chromosome 
aberrations such as deletions, dicentrics, multicentrics, rings, exchanges, breaks, and gaps 
are all induced (Mir et al. 1996). Bleomycin does not however induce sister-chromatid 
exchanges. There is no limit to the number of targets that bleomycin can attack once 
inside the cell. These attacks occur less than 30 seconds after the cell's membrane has 
been breached (Tounekti et al. 1993). Selective electropermeabilization has 
demonstrated that as little as a few hundred internalized bleomycin molecules are 
sufficient to induce cell death. 
There are a number of different types of cell death including necrosis and apoptosis. 
Necrosis is characterized by cell swelling, membrane ruptures, and the dissolution of 
organized structures, while apoptosis is marked by the shrinkage of cells and chromatin 
condensation (Tounekti et al. 1993). Necrosis is a far slower process in which the DNA 
is finally degraded by lysosomal enzymes and apoptosis, also referred to as programmed 
cell death, is a far swifter process where internal endonuclease is activated which then 
digests the DNA. A third type of cell death is observed following exposure to ionizing 
radiation. This is termed mitotic death in which the cell will complete one mitotic cycle 
before simply disintegrating. This is generally caused by exposure to low-dose ionizing 
radiation in which the cell remains viable, just no longer able to reproduce. Tounekti et 
19 
al. (1993) demonstrated that bleomycin acted in an identical fashion to ionizing radiation 
in how it attacked and killed cells. They were able to relate the number of bleomycin 
molecules internalized with the type of cell death produced. At low bleomycin 
concentrations, cells arrested in the G2/M phase and died a certain amount of time later. 
This period was equal to that of three cell doubling times and correlated well with mitotic 
cell death. For high concentrations of bleomycin, cell death occurred in an identical 
fashion to apoptosis. Tounekti et al. (1993) were also able to rule out several other 
possible contributors, such as free radical species and endonuclease in order to determine 
that cell death was a direct result of the bleomycin. This report concluded that 
approximately 3000 bleomycin molecules resulted in mitotic death, just as seen with low 
dose ionizing radiation and that 3 million internalized bleomycin molecules caused cell 
apoptosis, which is seen with high doses of ionizing radiation (Tounekti et al. 1993). 
There is no doubt as to the powerful cytotoxicity of bleomycin. Relatively few molecules 
can create severe damage once they have passed the cell membrane. These 
characteristics of bleomycin makes it ideally suited for use in photochemical 
internalization, where drugs are selectively released into the cell cytosol. The next 
requirement is the use of an appropriate membrane localizing photosensitizer. 
1.5 Aluminum phthalocyanine disulfonate (AlPcS2a) 
The photosensitizer chosen for this study is a metal-based phthalocyanine which 
belongs to a group of second-generation photosensitizers characterized by their high-
efficiency in the red visible wavelength. 
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The chemical structure of AlPcS2a gives this photosensitizer unique properties useful 
for PCI applications. Phthalocyanines are traditionally water insoluble, but the 
sulfonation of these molecules allows them to become biologically active (Berg et al. 
1989). Thus, AlPcS2a, which is sulfonated on two of its adjacent isoindole units, is water 
soluble and has an asymmetrical distribution of its polar groups (Edrei et al. 1998; 
Bonneau et al. 2004) (Fig. 8). The amphiphilic nature of AlPcS2a allows it to favorably 
interact with cell membrane structures. The photosensitizer alone possesses no local or 
systemic toxicity and is resistant to dimerization and aggregation once incorporated into 
the cell (Edrei et al. 1998; Maman et al. 1999). The primary advantage of AlPcS2a and 
other metallated phthalocyanines is their absorbance spectrum. 
SOi 
Figure 8. The structure of AlPcS2a-
In addition to its chemical properties, AlPcS2a's light absorbance and fluorescence 
characteristics are well suited for administration in biological tissue. AlPcS2a's peak 
absorbance in aqueous solution is 675 nm (Kunz et al. 2007). The optimum range of 
wavelengths for light penetration into tissue is between 650 - 680 nm (Edrei et al. 1998). 
Earlier, first-generation photosensitizers such as Photofrin, had peak absorbance around 
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630 nm, which resulted in about half the penetration depth (Chan et al. 1997). In 
addition to light absorbance in a favorable wavelength range, AlPcS2a has the benefit of 
low absorption in other parts of the visible spectrum (Chan et al. 1997). This reduces the 
risk to cutaneous photosensitization post-treatment. Compared to Photofrin, patients do 
not have to wait as long for the drug to clear their system. These absorption benefits only 
occur in the photosensitizer's monomer form, further supporting the need for low 
aggregation. The optimum absorption wavelengths for AlPcS2a in PBS are 672 nm and 
640 nm in the monomer and aggregate bands respectively (Edrei et al. 1998). 
Aggregation is a result of both chemical structure and localization of the photosensitizer 
within the cell. Changes in fluorescence localization are easily measured and can be used 
to determine changes in photosensitizer distribution. 
AlPcS2a primarily localizes in lipid membranes which favors cellular uptake by 
endocytosis (Edrei et al. 1998; Maman et al. 1999; Bonneau et al. 2004; Kunz et al. 
2007). The photosensitizer's amphiphilic chemical structure allows lipid bilayer 
penetration. The charged sulfonate group is oriented in the outer aqueous phase, where it 
is hydrated, and the neutral hydrophobic functional group becomes buried in the lipid 
structure (Maman et al. 1999). Transport across the lipid bilayer has been studied and 
found to be an extremely slow process (on the order of hours). Due to this slow nature of 
cellular uptake, passive diffusion of this molecule is highly unlikely (Maman et al. 1999; 
Bonneau et al. 2004). The primary mechanism for cellular uptake is the incorporation of 
AlPcS2a into endosomes and lysosomes. These endocytic vesicles are disrupted by 
photosensitizer-mediated production of singlet molecular oxygen which leads to the 
diffusion of AlPcS2a into the cytosol. The exact mechanism of this disruption will be 
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detailed in the following section. Uptake concentrations are highly dependent on 
environmental factors such as cell line, incubation conditions and time, medium pH, and 
the photosensitizer's lipophilicity (Edrei et al. 1998). Optimum incorporation occurs at a 
pH of 7.3, which correlates with typical physiological pH's (Maman et al. 1999). Berg et 
al. found that phthalocyanine photosensitizers' lipophilicity increased with decreasing pH 
which correlates with increased uptake (Berg et al. 1989). This would suggest a 
mechanism for selective uptake into tumor tissue which is often characterized by 
relatively lower pH levels compared to surrounding tissue due to hypoxia and waste 
product accumulation. Macrophages have also been shown to exhibit the highest uptake 
of AlPcS2a in several in vitro and in vivo studies (Kunz et al. 2007). Since macrophages 
constitute significant portions of the tumor matrix, this could also be another factor in 
AlPcS2a's preferential localization in tumor tissue. The tumor to peritumoral tissue ratio 
was measured by Chan et al. (1990) to be approximately 17, although such measurements 
are highly dependent on variables such as delivery method and time after administration. 
A mixture of various sulfonated phthalocyanines known as Photosens® has been used in 
Russian diagnostic and clinical phototherapy studies of various cancers since 1994 (Edrei 
et al. 1998). AlPcS2a is the most cytotoxic and thus most promising of the sulfonated 
phthalocyanines for use in phototherapy due to its high lipophilicity, low aggregation, 
optimal wavelength absorbance, and high selectivity for tumor tissue. 
1.6 Photodynamic therapy (PDT) 
PDT can be defined as the activation of a photosensitizer (PS) by an appropriately 
chosen light source that, in the presence of oxygen, produces destructive reactive oxygen 
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species (ROS) causing sufficient cellular damage and leading to cell death (Castano et al. 
2005a; Bonneau et al. 2004). PDT is an inherently selective treatment. Photosensitizers 
are chosen based on their ability to localize in targeted tissues, and light is selectively 
administered only to those regions of interest (Castano et al. 2004). The very short 
lifetime and range of ROS further contributes to PDT's high degree of localization. 
PDT has a long history in medicine, but only the most recent developments in cancer 
therapy will be discussed here. While PDT has been the subject of much research for 
several decades, clinical applications for a variety of cancers have only occurred over the 
past 30 years (Stylli and Kaye 2006a). PDT has been approved by the U.S. Food and 
Drug Administration for the treatment of microinvasive lung cancer, obstructing lung 
cancer, obstructing esophageal cancer, premalignant actinic keratosis, and age-related 
macular degeneration (Zhu and Finlay 2008). In addition, several studies have shown 
effective treatment of head and neck cancer, mesothelioma, Barrett's esophagus, prostate, 
and brain tumors (Zhu and Finlay 2008). PDT has been implemented in the treatment of 
brain tumors since Perria et al. treated human gliomas in 1980 (Madsen et al. 2002; Stylli 
and Kaye 2006a). PDT is generally used as an adjunct to traditional therapies of maximal 
tumor resection, ionizing radiation, and chemotherapy. Several groups have utilized PDT 
in this way, primarily with GBM and anaplastic astrocytoma, to better control infiltrative 
tumor cells in the vicinity of the resection margin (Dougherty et al. 1998; Madsen et al. 
2002). PDT is mostly used for the treatment of localized solid tumors that are easily 
accessible on the skin surface, in organs that can be accessed endoscopically, or deep-
seated lesions within organs treated by interstitial delivery of light (often directly after 
surgical resection) (Wilson 2002). 
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Light delivery is typically performed utilizing recently developed diode lasers. These 
lasers are reliable, compact, user friendly and relatively inexpensive which make them 
ideally suited for clinical use (Huang 2005). Laser light is focused using optical fibers 
that can treat both external and internal tumors with typical treatment times of 5-20 
minutes (Brown et al 2004). Muller and Wilson were the first to develop a cavitary 
illumination technique for the treatment of malignant gliomas in the 1990's that utilizes a 
balloon-like device filled with diffusing medium to evenly distribute the light (Huang 
2005; Stylli and Kaye 2005b). PDT still remains an inherently complex technology 
which is highly dependent on the tissue being treated as well as the characteristics of the 
photosensitizer used. 
Although it is not agreed upon what constitute the most important qualities of a PS, 
several chemical and structural characteristics can be identified as ideal for use in PDT. 
Characteristics of an ideal PS include: high tumor selectivity, strong phototoxicity, low 
dark toxicity, high singlet oxygen quantum yield, high intersystem crossing (ISC) yield, 
triplet-state energy greater than the energy required to excite oxygen (i.e. 94 kJ/mol), 
long wavelength absorption (600-800 nm), low light absorption at shorter wavelengths 
(400-600 nm), high tumor tissue retention, rapid clearance from surrounding normal 
tissue, high water solubility, low aggregation in biological environments, short interval 
between PS injection and illumination, and a commercially available pure chemical that 
is easily synthesized and highly stable (Almeida et al. 2004; Castano et al. 2004; Nyman 
and Hynninen 2004; Huang 2005; Stylli and Kaye 2006; Zhu and Finlay 2008). As with 
many biological systems, it is the balance of several characteristics that makes a PS 
suitable for PDT. While it is advantageous for a PS to have strong light absorption in 
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order to minimize its concentration, too strong an absorption leads to a self-shielding 
effect that reduces the treatment depth. Similarly, the PS must be stable enough to avoid 
rapid degradation (photobleaching), but not so stable that it significantly extends the 
patient's photosensitivity after the treatment is finished. Another important characteristic 
is chemical amphiphilicity. Amphiphilic PS have both hydrophobic and hydrophilic 
regions and are thus more photodynamically active since they tend to localize in 
hydrophobic-hydrophilic membrane interfaces and protein surfaces, as well as exhibit 
lower aggregation (MacDonald and Dougherty 2001). These qualities are important 
since they determine how and where a PS will localize within tumor cells. 
There are a large number of photosensitizers which target a variety of sub-cellular 
organelles. These targets include the plasma membrane, lysosomes, mitochondria, Golgi 
apparatus, and endoplasmic reticulum (Buytaert et al. 2007). Since PS do not generally 
localize in cell nuclei, PDT does not primarily cause DNA damage which lead to 
mutations and carcinogenesis as with other treatments like ionizing radiation and 
chemotherapy (Buytaert et al. 2007). 
As stated earlier, structure dictates localization, but there are a number of other 
qualities that govern PS localization. Molecular weight, ionic charge, PS concentration, 
incubation time, and target cell phenotype all factor into how a PS will distribute and 
localize (Castano et al. 2004). Thus the efficacy of any PDT treatment depends on many 
factors including the type of PS, its concentration, and localization. 
In addition to the type of PS, light dose (fluence), dose rate (fluence rate), and oxygen 
availability are critical determinants of PDT efficacy (Triesscheijn et al. 2006). As is the 
case with ionizing radiation, PDT is an oxygen-dependent therapy and therefore has 
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limited efficacy in hypoxic regions. Optimization requires judicious choice of 
parameters. In particular, oxygen levels are sensitively dependent on light fluence rates: 
high fluence rates result in rapid oxygen depletion and diminished PDT efficacy. 
PDT is a complex treatment modality requiring the presence of light, PS, and oxygen. 
Upon photoactivation, the PS is excited from its singlet ground state to a short-lived 
(nanoseconds) excited singlet state (Fig. 9). The excited PS can decay through three 
different transitions: (1) fluorescence, (2) internal conversion into heat, or (3) 
intersystem crossing (ISC) in which the excited electron's spin is inverted and the PS is 
converted to a triplet state (Nyman and Hynninen 2004; Castano et al. 2004). This first 
triplet state is longer-lived (microseconds) allowing it to interact through chemical 
reactions. The triplet state can decay through three different transitions as well: (1) 
phosphorescence and subsequent return to the ground state, (2) internal conversion into 
heat, and (3) non-radiative transfer of energy to molecular oxygen (MacDonald and 
Dougherty 2001). Oxygen has a unique triplet ground state and low excitation states 
which make this transfer possible. This transfer of energy takes form in two types of 
reactions. Type I reactions occur directly between the triplet state PS and the cellular 
substrate. This electron or proton-exchange produces reactive intermediates such as 
superoxide, hydroperoxyl, hydroxyl radicals, and hydrogen peroxide. Type I reactions 
typically occur only under anoxic conditions. If the cellular environment is sufficiently 
oxygenated, Type II reactions occur between the triplet state PS and ground state 
molecular oxygen. This process involves an electron spin exchange to convert triplet 
ground state oxygen into excited singlet state oxygen. The excited triplet state PS is 
converted back to the ground state. Thi,s entire process is illustrated in Figures 9 and 10. 
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Figure 9. PDT action mechanism. Once the ground state photosensitizer (PTS) is 
activated and excited (PTS ), deactivation occurs through fluorescence or intersystem 
crossing to the excited triplet state (3PTS). Energy is then lost via Type I or II reactions 
producing free radicals and ROS (Buytaert et al. 2007). 
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Figure 10. Jablonski diagram showing excitation and relaxation of a PS: (A) photo-
excitation, (B) fluorescence, (C) intersystem crossing, (D) phosphorescence, (E) non-
radiative transfer of energy to singlet oxygen, (F) substrate oxidation by singlet oxygen, 
(G) internal conversion (MacDonald and Dougherty 2001). 
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The photogenerated singlet state oxygen is the fundamental contributor to PDTs 
cytotoxicity. Singlet oxygen is a highly reactive oxidizer with a short half-life of less 
than 40 ns in biological systems which means its effective radius of action is less than 
0.02 urn (Castano et al. 2004; Stylli and Kaye 2005; Buytaert et al. 2007). The short 
lifetime of singlet oxygen limits biological damage to the immediate vicinity of the PS 
and therefore the organelle(s) affected. The type of cell death, therefore, is selectively 
dependent on intracellular PS distributions. 
As stated earlier, an ideal PS will have maximal light activation at a wavelength 
between 600-1300 nm - the so-called optical window (Castano et al. 2004) where light 
has significant penetration in biological tissues due to relatively low absorption and 
scattering of major tissue constituents (Fig. 11). 
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Figure 11. 'Optical window' in tissue. Absorption spectra for water, oxy- and 
deoxyhemoglobin, and melanin (Castano et al. 2004). 
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The mode of cell death caused by PDT is determined by cell type, PS localization, 
and light fluence (Castano et al. 2005a). It has generally been found that low-fluence 
PDT leads to apoptosis while higher fluences will produce proportionately more necrosis. 
Both modes of cellular death lead to tumor destruction through a direct cellular toxic 
effect, vascular damage, or an immune reaction (Castano et al. 2005; Stylli and Kaye 
2005). All three mechanisms of tumor destruction begin with the production of ROS by 
activation of a PS. The first mechanism is the result of ROS-induced necrosis or 
apoptosis of a significant proportion of cells within the tumor. The second mechanism 
occurs indirectly when PDT-induced damage of the tumor vasculature restricts the supply 
of nutrients and oxygen, which ultimately leads to tumor infarction. PDT has also been 
shown to cause primary vascular leakage further restricting the tumor's ability to sustain 
itself. PDT has been found to require a functioning immune system to illicit complete 
tumor response. An immune response to cancer, induced by PDT, is explained by the 
induction of inflammation which initiates anti-tumor activity within the tissue followed 
by a long-term immunological response (Castano et al. 2005b). 
While many of the tumor responses to PDT are not well understood, the net cytotoxic 
effect still demonstrates PDTs ability to act as a potent adjunct therapy with many 
advantages over those currently employed. PDT is not limited by cumulative or 
maximum dose considerations (except for heat generation which can be controlled 
through fractionation), allowing repeated applications that can be combined with other 
therapies. There are few significant side effects and PDT is not known to cause 
mutations or be carcinogenic. In fact, normal tissue readily heals after treatment. The 
primary drawback of PDT is the poor penetration depth of light in tissues which limits 
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the treatment to relatively small tumors easily accessible by intracavitary light delivery 
methods. 
1.7 Photochemical internalization (PCI) 
PCI is a technique which utilizes the photochemical properties of PDT for the 
enhanced delivery of macromolecules into the cell cytosol. These macromolecules lack 
the ability to naturally permeate intracellular barriers such as the plasma and endocytic 
membranes (Berg et al. 2007). Due to this inability, they are expected to be internalized 
through endocytosis, localized in late endosomes and lysosomes until they are degraded 
by hydrolytic enzymes. PCI relies on specific PS that preferentially localize in vesicular 
membranes. Upon light activation, the ROS produced act to permeabilize the endocytic 
membrane allowing the release of its contents. In this way, the macromolecules are 
delivered into the cytosol in a biologically active form (Berg et al. 2006). The precise 
molecular nature of membrane permeabilization is still not fully understood, with some 
reports identifying membrane protein damage as being more important than the oxidation 
of membrane lipids (Hogset et al. 2004). However, this technique can be applied to 
various molecules and is not inhibited by their size or charge. Ideally, molecules chosen 
for this technique would have no ability to adversely affect non-targeted cells (Hogset et 
al. 2004). This would restrict the macromolecular activities to those inside 
photoactivated cells, sparing all others. 
Only specialized PS can be used in PCI. Most importantly, the PS must demonstrate 
preferential localization in endocytic membranes and exhibit low aggregation (Hogset et 
al. 2004). The PS should localize specifically in the membrane structure itself and not 
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simply the endocytic lumen. This is important in order for the short-lived ROS to cause 
membrane damage. In addition, if the PS is also present inside the compartment near the 
molecules to be delivered, there is an increased chance of the ROS oxidizing the 
molecules. Obviously, no PCI effect can be achieved if the molecules are destroyed prior 
to their release into the cytosol. The aggregation state of the PS is also of importance. A 
highly aggregated PS will undergo endocytosis, not incorporation into the membrane 
structure. Highly aggregated PS are also inhibited in their transfer of energy to molecular 
oxygen. For these reasons, amphiphilic PS are ideally suited for PCI due to their 
hydrophobic and hydrophilic parts resulting in membrane localization with little risk of 
passage through to the interior of the endosome (Berg et al. 2005b). The basic process is 
illustrated in Figure 12. 
Figure 12. PCI of bleomycin molecules through the activation of the photosensitizer, 
AlPcS2a: (1) the PS is localized in the endocytic membrane, (2) photoactivation creates 
an excited state PS, (3) the PS activates singlet oxygen and other ROS, (4) which cause 
permeabilization of the endocytic membrane and subsequent release of bleomycin into 
the cytosol. 
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AlPcS2a and bleomycin were both chosen for this study due to their ideal qualities for 
use in PCI. AlPcS2a is an amphiphilic PS known to localize in endocytic vesicle 
membranes and absorb in the far-red (670 nm) region (Castano et al. 2004; Hogset et al. 
2004; Berg et al. 2006, 2007; Kunz et al. 2007). As for bleomycin, this chemotherapeutic 
is known to have poor cellular uptake resulting in its accumulation in endocytic vesicles 
(Hogset et al. 2004; Berg et al. 2007). It has also been determined by several studies that 
AlPcS2a-mediated PCI of bleomycin results in synergistic inhibition of tumor growth in 
several in vivo and in vitro applications (Hogset et al. 2004; Berg et al. 2005, 2007). 
These reports are encouraging for this study and its application to the PCI of bleomycin 
in glioma cells. 
1.8 Scope of study 
The primary objective of this thesis is to examine the ability of PCI to enhance the 
efficacy of the chemotherapeutic drug, bleomycin, in both rat glioma monolayers and 
human glioma spheroids. In both cases, the plasma membrane localizing photosensitizer, 
aluminum phthalocyanine disulfonate (AlPcS2a), will be used. It is hypothesized that: 
(1) AlPcS2a is an effective photosensitizer for PDT on both F98 monolayers and ACBT 
spheroids, (2) high concentrations of the chemotherapeutic agent, bleomycin, are capable 
of producing significant toxicity in both in vitro glioma systems, and (3) the combination 
of AlPcS2a-PDT and bleomycin, i.e. PCI, exhibits a synergistic toxic effect on both 
glioma cell lines compared to either treatment modality alone. 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 Cell Lines 
All experiments were performed in vitro utilizing two cell lines, F98 and ACBT. All 
work was done inside a Labconco Class II Biohazard Cabinet (Labconco Corp., Kansas 
City, MO) at the University of Nevada, Las Vegas (UNLV) unless otherwise specified. 
Cells were incubated at 37°C, 5.0% C02, and 95% humidity inside a VWR incubator 
(VWR International, LLC. West Chester, PA). Both cell lines were continually kept in 
Gibco Dulbecco's Modified Eagle Medium (DMEM) High Glucose IX (Invitrogen 
Corp., Carlsbad, CA) with 10% heat-inactivated fetal bovine serum (FBS), 25mM 
HEPES buffer (pH 7.4), penicillin (100 U/ml), and streptomycin (100 ug/ml). All 
monolayer cells were passed using the same technique. After the confluency was 
checked, the flask was carefully emptied of all media and washed with 5mL of Gibco 
phosphate buffered saline (PBS) with pH of 7.2 (Invitrogen Corp., Carlsbad, CA). Next 
lmL of Gibco 0.25% Trypsin-EDTA (Invitrogen Corp., Carlsbad, CA) was added and 
left in contact for 5 minutes. Trypsin is a proteolytic enzyme, which acts to detach the 
cells from the flask surface. After this, while holding the flask horizontal, it was tapped 
briskly against a solid surface in order to dislodge the cells. Next, 4 mL of DMEM was 
added to the flask. The contents were then pipetted up and down several times and 
transferred to a 15 mL centrifuge tube. After vortexing for approximately 10 seconds, 
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200 uL of this solution was added to 4.8 mL of DMEM inside a new flask. Two flasks 
were seeded in this manner, which resulted in approximately 100,000 cells passed to each 
new flask. This ensured a consistent supply of cells for all the experiments. 
F98 is a rat glioma cell line, maintained as a monolayer and established from gliomas 
induced in CDF (Fischer) rats. These gliomas were induced through exposure to ethyl-
nitrosourea and established by surgically removing the tumor, mincing the tissue, 
trypsinizing, and cultivating in Eagle medium (Ko et al. 1980). The F98 monolayer cells 
were maintained in 25 cm2 BD Falcon tissue culture flasks with 0.2 um vented caps (T25, 
Beckton, Dickson and Company, Franklin Lakes, NJ). Monolayer cells were passed 
twice per week, in order to maintain confluences between 40 and 80%. The confluency 
is a subjective measurement of the percentage of the flask's area covered by the cells. As 
this is a subjective measurement, the figure is always recorded with a 10% range. 
ACBT cells were derived from a human grade IV GBM (G. Granger, University of 
California, Irvine) and were analyzed both as monolayers and spheroids. ACBT 
monolayers were kept in T25 flasks and passed once per week. Spheroids were formed 
by liquid overlay in Fisherbrand 100 xlOO xl5 mm square dishes (Fisher Scientific, 
Pittsburgh, PA) that were coated with 10 mL of 2% agarose (BioWhittaker Molecular 
Applications, Rockland, ME). A solution of cells was extracted as when passing cells. 
For spheroid formation, as many cells as possible are desired, therefore, the entire 
solution was added to the Petri dish along with 20 mL of DMEM. Spheroids began 
forming after one week of incubation. Stocks of four to eight Petri dishes containing 
spheroids were kept to maintain a sufficient supply. The DMEM in each dish was 
changed twice per week, removing and replacing 10 to 15 mL. 
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2.2 Monolayer survival plating 
Treatment toxicity for all monolayers was determined through clonogenic assay 
techniques. Following the treatments, cells were extracted from the T25 flasks just as 
with passing and pipetted into 15 mL tubes. After vortexing for approximately 10 
seconds, 100 uL was pipetted into a Coulter cup containing 9.9 mL of IsoFlow Sheath 
fluid (Beckman Coulter Inc., Fullerton, CA). Each cup was counted in a Beckman 
Coulter Particle Count and Size Analyzer Model Z2 (Beckman Coulter Inc., Fullerton, 
CA). The contents of each cup were gently stirred followed by two consecutive counts, 
stirred again, and counted two more times. The average of these four counts was 
calculated to yield the total cells per milliliter in each solution. Once the concentration 
was found, 500 uL from each tube was taken and added to 4.5 mL of DMEM in order to 
create a 10% dilution. This was performed in order to attain the desired concentration of 
cells in medium, so that between 100 and 800 uL of cells were added to 4 mL of DMEM 
in a 60 x 15 mm Petri dish (Corning Inc., Corning, NY). Each survival group has a 
specific number of cells to be plated. Some survival groups have two or three different 
cell count numbers to be plated. To calculate the exact volume of cells needed for plating 
in each dish, the number of cells desired was divided by the measured cell concentration. 
After the cells were pipetted into each Petri dish, the contents were gently swished back 
and forth then side to side in order to maintain even cell coverage within the dish. All the 
dishes were then incubated for 7 days. After this time, the media was decanted and the 
dishes stained with crystal violet. Using a light microscope, any colonies that formed in 
the dishes were counted. A colony was considered any grouping of 50 or more cells. All 
colonies were scored and survival rate was calculated by normalizing to the control. 
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Therefore, all control survival rates reported here are exactly 100% and some treatment 
survival rates may be greater than 100% due to statistical uncertainty. 
2.3 Spheroid growth analysis 
The effect of treatment on the spheroids was determined by following spheroid 
growth post-treatment. This was accomplished by pre-selecting spheroids, whose 
average cross-sectional diameters were between 400 and 500 um. Spheroid diameter was 
measured using a microscope with a calibrated eyepiece micrometer. Two perpendicular 
diameter measurements were made to the nearest 50 jam, and the average was recorded. 
For each treatment group, 20 to 30 spheroids were placed in a 35 x 10 mm Petri dish 
(Beckton, Dickson and Company, Franklin Lakes, NJ) with 2 mL of DMEM. After 
treatment, 20 spheroids from each dish were extracted and placed into separate wells of a 
Costar 48 well cell culture cluster (Corning Inc., Corning, NY). Each well was coated 
with 250 uL of agarose and filled with 750 uL of DMEM. In this way, each individual 
spheroid's growth could be monitored. 
Spheroid growth was monitored over a 28 day period, beginning 24 hours after 
treatment. The initial diameter measurement was taken 24 hours after treatment, and 
subsequent measurements were taken twice per week for a total of nine measurements. 
Following each measurement, approximately 500 uL of DMEM was removed from each 
well and replaced with fresh DMEM to ensure the spheroids were given adequate 
nutrients. Spheroids demonstrating a diameter increase in excess of 50 urn between 
weekly measurement intervals were scored viable. 
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2.4 Bleomycin toxicity 
Bleomycin (Sigma, St. Louis, MO) toxicity was investigated in F98 monolayers and 
ACBT spheroids. In both cases, the drug was added to DMEM to yield concentrations 
from 0.1-10 ug/mL. In all cases, cells were incubated in bleomycin and DMEM for four 
hours. Following incubation, all monolayer cells were harvested and plated for 
clonogenic survival as previously described. ACBT spheroids were placed in individual 
wells filled with DMEM and monitored for growth as previously described. 
2.5 PDT toxicity 
The effects of PDT on both the F98 and ACBT cell lines were determined using 
similar protocols. First, a photosensitizer was administered, and then a light dose was 
given. Cells (or spheroids) were incubated for 18 hours with 1 |ig/mL of AlPcS2a 
(Frontier Scientific, Inc., Logan, UT) and DMEM. Following incubation, the media was 
removed and the cells (or spheroids) were placed in DMEM only. Next, the cells (or 
spheroids) were irradiated using a Class 4 photodiode laser (High Power Devices, Inc., 
North Brunswick, NJ) coupled to a 200 um diameter optical fiber containing a micro-
lens. The diode laser was calibrated to emit light at a wavelength of 670 nm. All cells 
(or spheroids) were exposed to an irradiance of 5 mW/cm . The total radiant exposure 
was determined by exposure time and ranged from 0.75 to 6 J/cm2. The effects of PDT 
on cells and spheroids were determined using clonogenic survival and growth kinetics, 
respectively (as previously described). 
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2.6 PCI toxicity 
In order to test for a PCI effect, cells (or spheroids) were first incubated in 1 jig/mL 
of AlPcS2a for 18 hours, just as with PDT. After this, cells (or spheroids) were incubated 
with either 0.1 or 0.25 ug/mL of bleomycin in DMEM for four hours. Next, the cells (or 
spheroids) were irradiated with 670 nm light (irradiance of 5 mW/cm and radiant 
exposure of 1.5J/cm ) as described in section 2.4. The effects of PCI on cells and 
spheroids were determined using clonogenic survival and growth kinetics, respectively 
(as previously described). 
2.7 Flow cytometry 
Flow cytometry was used to determine the fraction of viable, apoptotic, and necrotic 
cells. The two different fluorescent labels used were Annexin V-FITC (Beckton, 
Dickson and Company, Franklin Lakes, NJ) to distinguish apoptotic cells, and propidium 
iodide (PI, Sigma, St. Louis, MO) to label necrosis. Unlabeled cells were assumed to be 
viable. The procedure to prepare both monolayer and spheroid cells was identical, except 
for how the cells were brought into solution. 
All monolayer cells were first harvested into a DMEM solution, while spheroids were 
incubated in 15 mL tubes for 20 minutes in 500 uL of a one-to-one mixture of 1% 
collagenase (Invitrogen Corp., Carlsbad, CA) in Hanks' Balanced Salt Solution lx 
(HBSS with Ca2+ and Mg2+, Invitrogen Corp., Carlsbad, CA) to dispase (Beckton, 
Dickson and Company, Franklin Lakes, NJ). After incubation, the spheroids were 
vortexed for 5 seconds and 5 mL of PBS was added. The tubes were then centrifuged in 
a Beckman GS-6 centrifuge (Beckman Coulter Inc., Fullerton, CA) for five minutes at 
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1000 rpm. The PBS was then decanted, 5 mL of PBS was added and the tube was 
vortexed for 5 seconds. The rubes were centrifuged again, the PBS decanted, and 500 uL 
of PBS was added. For a final time the tubes were centrifuged, the PBS decanted, and lx 
binding buffer (Beckton, Dickson and Company, Franklin Lakes, NJ) was added to 
achieve a final concentration of 10 cells/mL. Next, 100 uL of the solution was 
transferred along with 400 uL of lx binding buffer to a 5 mL BD Falcon tube. The two 
labels were then added with 5 uL of Annexin V-FITG and 10 uL of 100 ng/mL 
concentration PI. The solutions were gently agitated, and then incubated for 15 minutes 
at room temperature in the dark. 
For each experiment, a set of control solutions was also prepared. One control 
remained unlabeled, the next labeled only with Annexin V-FITC, and the third labeled 
only with PI. Finally, after 15 minutes of incubating in the dark, each tube was analyzed 
in a Beckton Dickson FACSCalibur (Beckton, Dickson and Company, Franklin Lakes, 
NJ) flow cytometer along with CellQuest software. 
2.8 Two-photon fluorescence microscopy (TPFM) 
All TPFM experiments were performed at the Beckman Laser Institute, University of 
California, Irvine (UC, Irvine). Two-photon fluorescence images were taken of ACBT 
spheroids of various diameters and subjected to various treatments. The spheroids were 
co-stained with Hoechst 33342 (Invitrogen, Carlsbad, CA) and Ethidium Homodimer 1 
(El 169, Invitrogen, Carlsbad, CA) 48 hours after treatment. The stains were 
administered in 5 and 1 (j.g/mL concentrations in 2 mL of medium for Hoechst and 
Ethidium Homodimer respectively. Spheroids were incubated for 1 hour and then 
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washed three times with HBSS before being transferred to new 35 x 10 mm Petri dishes. 
The spheroids were then fixed by adding 2 mL of 5% formaldehyde in ultrapure water to 
each dish. After 1 hour, five spheroids from each treatment group were pipetted into 
separate wells of a Costar 96 well cell culture cluster (Corning Inc., Corning, NY) which 
were each filled with 250 uL of PBS. The spheroids were imaged using an inverted laser 
scanning microscope (LSM 510 META, Zeiss, Oberkochen, Germany) with a 20x /0.5 
NA lens (EC Plan-Neofluar, Zeiss, Oberkochen, Germany). The blue Hoechst 
fluorescence from all cell nuclei was imaged using 800 nm two-photon excitation and 
390-465 nm detection. The red Ethidium Homodimer fluorescence from necrotic nuclei 
was imaged confocally with 488 nm excitation and 576-640 nm detection. Scans were 
made at planes 30-50 um into each spheroid with simultaneous excitation of the two 
dyes, and the images were pseudo-colored blue and red. 
2.9 Statistical analysis 
All data was analyzed and graphed using Microsoft Excel. The arithmetic mean and 
standard deviation were used throughout to calculate averages and errors. Statistical 
significances were calculated using the Student's t-test as well as the Welch's t-test. Two 
values were considered distinct when their p-values were below 0.05. 
Synergism was calculated when analyzing PCI treatments. Equation 2.1 was used to 
determine if the PCI effect was synergistic, antagonistic, or additive. 
SF°xSFh . . . 
a
 =
 SFa„ (Eq-2.1) 
In this scheme SF' represents the survival fraction for a specific treatment. If two 
treatments are to be compared, the survival fractions of each separate treatment are 
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multiplied together and then divided by the survival fraction when both treatments were 
applied together. The resulting number (a) describes the cumulative effect. If a > 1, the 
result is synergistic. If a < 1, the result is antagonistic, and if a = 1 the result is simply 
additive. 
42 
CHAPTER 3 
RESULTS 
3.1 AlPcS2a and bleomycin toxicity in F98 monolayers 
The first priority was to determine the relative drug toxicities of the photosensitizer, 
AlPcS2a, and bleomycin in the F98 rat glioma cell line. F98 monolayer cells were 
incubated for 18 hours in DMEM with increasing concentrations of AlPcS2a-
Photosensitizer concentrations of 0 (control), 0.5, 1, 2, 4, 8, 16, 24, 32, and 64 ng/mL 
were administered. All experiments were performed in the dark with minimal light, and 
the data demonstrated no correlation between photosensitizer concentration and percent 
survival (Fig. 13). 
The relative toxicity of bleomycin was also measured after a four hour incubation 
period. The concentrations of bleomycin tested were: 0.1, 0.25, 0.5, 0.75, 1, 5, and 10 
|j.g/mL. As expected, there was a noticeable decrease in survival fraction directly 
correlated to increasing concentration of bleomycin. The LC50 was shown to occur at 
approximately 0.5 ng/mL. Concentrations of 0.1 and 0.25 ug/mL resulted in survival 
rates of approximately 80 and 60%, respectively (Fig. 14). 
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3.2 PDT toxicity in F98 monolayers 
The F98 monolayer cells were incubated for 18 hours in a concentration of 1 ug/mL 
of AlPcS2a. Six different groups were analyzed. The first group was a control containing 
no photosensitizer. The second group, known as the dark control, was incubated in 
AlPcS2a and no light was administered. This was used to ensure that the effects seen 
were those solely of the photosensitizer activated by the laser light. Therefore, the dark 
control group should exhibit 100% survival. The remaining four groups were incubated 
in AlPcS2a, and subjected to increasing light exposures. The results showed a clear 
correlation between increasing light exposure and decrease in survival fraction with an 
LD50 of approximately 2.5 J/cm2. An exposure of 1.5 J/cm2 resulted in a survival rate of 
approximately 80% (Fig. 15). The p-values (Table 3.1) show no distinction between the 
control and the dark control groups. There is also no statistical distinction between the 
dark control and the first PDT treatment with 0.75 J/cm2 of light. 
Table 3.1: P-values for F98 PDT toxicity 
Two Groups Being Compared 
Control / Dark Control 
Dark Control / AlPcS2a + 0.75J 
AlPcS2a + 0.75J / AlPcS2a + 1.5J 
AlPcS2a+1.5J/AlPcS2a + 3J 
AlPcS2a + 3J / AlPcS2a + 6J 
p-value 
0.9209 
0.6929 
0.0106 
0.0000 
0.0098 
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3.3 PCI toxicity in F98 monolayers 
The final step in evaluating toxicities in the F98 monolayer was to determine the 
effect of PCI treatment and to compare with previous results of bleomycin alone and 
PDT. All PCI survivals included nine separate treatment groups. These groups included 
previously studied parameters such as a control, AlPcS2a dark control, 0.1 ug/mL 
bleomycin, 0.25 ug/mL bleomycin, and 1.5 J/cm2 PDT with 1 ug/mL AlPcS2a- The 
inclusion of these five groups allowed for direct comparison to PCI, as well as 
confirmatory comparisons to previous experiments. The remaining four treatment groups 
were used to both eliminate possible unwanted drug interactions, as well as illustrate the 
desired PCI effect. The first unwanted interaction was between AlPcS2a and bleomycin 
alone. For this group, the photosensitizer and bleomycin were incubated as with the other 
experiments, however no light was administered. Since the PCI effect should only be 
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present when the photosensitizer is activated, this group should show identical toxicity to 
that of bleomycin alone. The other unwanted interaction investigated was that of 
bleomycin and the laser light. No photosensitizer was added to this group. Bleomycin 
was not expected to be activated or degraded in the presence of light; therefore, this 
group should also behave identical to that of bleomycin alone. 
For the two PCI effect groups, identical concentrations of AlPcS2a, as well as radiant 
exposures were used. One group was incubated in 0.1 ug/mL and the other in 0.25 
|ag/mL of bleomycin. Both PCI treatment groups should therefore be comparable to the 
two concentrations of bleomycin alone and PDT treatment (Fig. 16). The p-values shown 
in Table 3.2 show statistically significant differences in survival between monolayers 
subjected to both PCI regimens and either PDT-only or BLM-only treatments. 
Table 3.2: P-values for various F98 PCI toxicity groups 
Two Groups Being Compared p-value 
Control / AlPcS2a (Dark) 0.9193 
0.1 BLM/ 0.25 BLM 0.1325 
0.25 BLM / AlPcS2a + 0.25 BLM 0.7226 
0.25 BLM 7 0.25 BLM+1.5J 0.9586 
0.1 BLM / AlPcS2a + 1.5J (PDT) 0.4651 
0.25 BLM / AlPcS2a + 1.5J (PDT) 0.2469 
AlPcS2a + 1.5J (PDT) / AlPcS2a + 0.1 BLM + 1.5J (PCI) 0.0183 
AlPcS2a + 1.5J (PDT) / AlPcS2a + 0.25 BLM + 1.5J (PCI) 0.0013 
0.1 BLM / AlPcS2a + 0.1 BLM + 1.5J (PCI) 0.0116 
0.25 BLM / AlPcS2a + 0.25 BLM + 1.5J (PCI) 0.0205 
AlPcS2a + 0.1 BLM + 1.5J (PCI) / AlPcS2a + 0.25 BLM + 1.5J (PCI) 0.0257 
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Since PCI is a technique which relies on the combination of drug and photosensitizer, 
the resultant toxicities should show more than an additive effect between bleomycin and 
AlPcS2a-PDT. The degree of synergism was calculated by comparing the survival 
fractions of bleomycin and PDT alone with that of the PCI treatment (Table 3.3). As 
evidenced from equation 2.1, the higher the a value, the greater the degree of synergism. 
Table 3.3: Degree of potentiation between PDT and bleomycin for F98 monolayers. 
PCI Survival a +/-
AlPcS2, + 0.1BLM+1.5J(PCI) 1.454 0.1433 
AlPcS2a + 0.25 BLM + 1.5J (PCI) 2.432 0.2286 
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3.4 ACBT Spheroid Growth Assays 
The monolayer results clearly demonstrated a PCI effect in the F98 rat glioma cell 
line. The next step was to determine whether such an effect could be elicited in a more 
complex model. This was done by performing growth assays on spheroids of the human 
glioma cell line, ACBT. 
A total of seven groups were followed simultaneously in order to better compare the 
various toxicities. The seven groups included: a control, AlPcS2a dark control, 0.1 
fig/mL bleomycin, 0.25 jig/mL bleomycin, 1.5 J/cm PDT with 1 (xg/mL AlPcS2a, and 
PCI groups with 0.1 and 0.25 ug/mL bleomycin. Each PCI group was incubated in 1 
Ug/mL AlPcS2a and irradiated with 1.5 J/cm . Based on the monolayer results (Figures 
3.1 and 3.2), sub-optimal bleomycin and light doses were chosen in order to optimize the 
PCI effect. The exclusion of two groups (AlPcS2a + bleomycin and bleomycin + 1.5 
J/cm2) was made since no effect was observed in the F98 experiments. 
The p-values (Appendix I) are illustrative in showing how many days post-treatment 
that the spheroids' diameters have measurable statistical differences in growth. In many 
cases, the spheroid diameter growth difference was evident after the fifth day. For others, 
the difference did not appear until the 12th day. For example, the 0.25 ug/mL bleomycin 
and the PCI with 0.25 ug/mL bleomycin groups demonstrated similar growth patterns 
until the 12th day. After this point, a clear distinction was discernible, showing a 
reduction in growth of the latter. A line graph of the average spheroid diameter over time 
after treatment (Fig. 17) clearly shows a growth delay in the PCI treatment groups. All 
spheroids in the seven different groups began with an average diameter of approximately 
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450 urn and grew to a final diameter between 900 and 1300 um by the final measurement 
on the 29th day. 
The control group showed the most accelerated growth rate over this time, while both 
PCI treatment groups demonstrated the slowest growth. The growth pattern illustrated in 
Figure 17 was consistent with Gomperzian growth (initial exponential growth followed 
by a linear phase and finally reaching an asymptotic limit). It is easier to see the initial 
differences in diameter, if only the first eight days post-treatment are shown (Fig. 18). 
Already after five days, a difference in the growth rates was discernible. 
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It is also instructive to look at the viability of the ACBT spheroids from the 
perspective of percent growing versus time (Fig. 19). This is illustrated by plotting the 
percentage of spheroids showing growth, thus still viable, between weekly measurement 
periods. Weeks 1, 2, 3, and 4 correspond to those measurements taken on days 8, 15, 22, 
and 29 respectively. 
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The degree of potentiation between PDT and bleomycin is shown in Table 3.4. The 
data suggest an additive effect for the combination of 0.1 jig/mL bleomycin and PDT, 
while a synergistic effect is observed during the first two weeks post-treatment for the 
0.25 ug/mL bleomycin and PDT group. Subsequent proliferation of cells not damaged 
by the treatments resulted in MTS regrowth, as indicated by the loss of synergism in 
weeks 3 and 4. 
Table 3.4. Degree of potentiation between PDT and bleomycin for ACBT spheroids 
AlPcS2a + 0.1 BLM 
+ 1.5J (PCI) 
AlPcSza + 0.25 BLM 
+ 1.5J (PCI) 
Week 
1 
a 
1.346 
1.657 
+/-
0.3203 
0.3970 
Week 
2 
a 
1.284 
1.983 
+/-
0.3056 
0.4748 
Week 
3 
a 
1.128 
1.395 
+/-
0.2684 
0.3339 
Week 
4 
a 
1.104 
1.284 
+/-
0.3060 
0.3720 
3.5 Determination of spheroid cell viability by flow cytometry 
Flow cytometry was utilized to examine the effects of treatment on cellular viability. 
This was performed by examining the percentage of viable, necrotic, and apoptotic cells 
as a function of treatment for each of the seven groups considered in section 3.4 (Fig. 20). 
All spheroids were between 450 and 550 um in diameter. The percentage of viable cells 
was slightly lower in the PCI groups, while a small increase in the apoptotic fraction was 
noted in these two groups. 
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3.6 Two-photon fluorescence microscopy 
The results of two-photon fluorescence images demonstrated a qualitative 
enhancement in the toxicity of PCI compared to bleomycin or PDT-only treatments 
alone. This was inferred from the high proportion of red fluorescing cells (suggestive of 
necrosis) observed from the PCI-treated spheroids (Fig. 2Id). By comparison, a smaller 
number of red fluorescing cells was observed from PDT-only spheroids (Fig. 21c). As 
illustrated in Figs. 21a and b, virtually no necrotic cells were observed in control and 
bleomycin-only spheroids. 
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Figure 21. Two-photon fluorescence microscopy images of ACBT spheroids stained 
with Hoechst 33342 (grey) and Ethidium Homodimer (white, necrosis). Images a and b 
were taken at a depth of 20 urn and images c and d at 30 and 40 um, respectively. 
Spheroids were fixed 48 hours after treatment: (a) control, (b) 0.1 ng/mL bleomycin, (c) 
1.5 J/cm2 PDT, (d) PCI with 0.1 ng/mL bleomycin + 1.5 J/cm2. Field of view for all 
images was 400 x 400 urn. 
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CHAPTER 4 
CONCLUSIONS 
The results of this study lead to several conclusions about the responses of two 
different cell culture models to PCI, a novel drug delivery technique. F98 monolayer 
colony formation assays revealed the ability of both bleomycin and AlPcS2a-PDT to elicit 
significant cytotoxic effects. They also showed the synergistic nature of PCI treatment 
over both bleomycin and PDT alone. The results of these experiments also served to 
eliminate the possibility of extrinsic effects between bleomycin and AlPcS2a or 
bleomycin and light. ACBT spheroid growth kinetics demonstrated that bleomycin and 
PDT were both inefficient treatments of MTS at low doses, but that together a synergistic 
effect caused significant growth retardation. The growth curves also supported the 
modeling of ACBT spheroids according to Gompertzian growth characteristics. 
Flow cytometry and two-photon fluorescence microscopy both aided in qualifying the 
internal composition of spheroids after various treatments. Flow cytometry data showed 
that PCI treatment caused a decrease in the percentage of viable cells and an increase in 
the apoptotic fraction. The TPFM images illustrated the increased formation of necrotic 
cells in both PDT and PCI treated spheroids. The significant increase in PCI-induced 
necrosis would suggest a synergistic interaction for the PCI compared to PDT and 
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bleomycin alone due to the smaller number of necrotic cells observed in bleomycin-only 
and PDT-only treated spheroids. 
All these findings can be generalized to describe a major difference between the two 
cell culture models. For each of the experiments, monolayer cells demonstrated higher 
sensitivity to the various treatment modalities. This can be attributed to the fundamental 
differences between the two models. Monolayers lack intercellular communication and 
are actively proliferating in optimal growth and re-oxygenation conditions. In particular, 
a readily available supply of oxygen plays a major role in both PDT and PCI cytotoxicity. 
Monolayer cells have high morphological homogeneity exhibiting identical growth 
within the model. In contrast, MTS have developed significant amounts of extracellular 
matrix and present three distinct phases of cell growth (proliferating, quiescent, and 
necrotic) within each spheroid. MTS also exhibit nutrient, pH, and oxygen gradients. 
While many of the specific interactions are not fully understood, these differences 
clearly confer an increased resistance of MTS to various chemotherapeutic and ionizing 
radiation treatments. This is often attributed to MTS resistance to apoptosis and the 
ability for quiescent cells to better repair sublethal and potentially lethal damage which 
are characteristic of low-dose ionizing radiation. Since bleomycin is known for inducing 
apoptosis and has cytotoxic similarities to ionizing radiation, these key differences 
between monolayers and MTS are especially important for this study. 
While the synergistic effect was less pronounced in MTS, these findings bode well 
for possible clinical applications of PCI in the treatment of GBM. The current regimen of 
surgical resection followed by external beam radiation and chemotherapy could be 
augmented to include PCI therapy. Post surgical applications could selectively target 
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glioma cells that were unresectable as well as infiltrative cells two or more centimeters 
from the resection cavity. As this treatment is not limited by cumulative dose 
restrictions, it could be easily incorporated into the treatment regime. 
It would be instructive to further investigate several aspects of the findings in this 
study. It was demonstrated that PCI can be effectively used to enhance the delivery of 
bleomycin into glioma cells. The next step is to optimize the observed effects in the 
ACBT spheroid model. This would include optimal concentrations of bleomycin, light 
doses for AlPcS2a-PDT, and their combination in PCI. Better characterization of the 
ACBT spheroid model would also present a clearer picture with regard to spheroid 
response to treatment. Utilizing theoretical Gompertz growth equations based on 
experimental data could better illustrate expected values such as diameter at onset of 
necrosis formation, viable rim thickness, and maximum attainable volume. These values 
would aid in the analysis of spheroid growth kinetics. The final step would be in vivo 
studies to test the optimizations and growth predictions. 
In conclusion, the results of these experiments clearly demonstrate the synergistic 
effects of PCI in two different in vitro glioma cell models. Sub-optimal doses of 
bleomycin and PDT in monolayers demonstrated a decreased efficiency in MTS. Even at 
these sub-optimal levels, PCI was very effective, resulting in 35% spheroid viability two 
weeks post-treatment. This result is extremely encouraging considering the low doses of 
bleomycin and PDT administered. PCI can clearly be used to substantially enhance the 
delivery of bleomycin in malignant glioma cells resulting in a significant reduction in cell 
survival. Additional animal studies will be required in order to fully understand the 
implications of these results. 
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APPENDIX I 
ACBT SPHEROID GROWTH ASSAY P-VALUES 
P-values for spheroid diameter measurements versus days post treatment are given in 
the table below. For simplicity, the experimental groups are labeled A through G as 
follows: control (A), AlPcS2a dark control (B), 0.1 [ig/mL bleomycin (C), 0.25 ug/mL 
bleomycin (D), 1.5J PDT with 1 ug/mL AlPcS2a (E), PCI with 0.1 ug/mL bleomycin (F), 
PCI with 0.25 ug/mL bleomycin (G). Therefore, column AB signifies p-values between 
the measurements of groups A and B for days 1 - 29. 
Table Al. P-values for ACBT spheroid diameter growth assay. 
Two Groups Being Compared 
AB AC AD AE AF AG BC BD BE BF BG 
Dayl 0.254 0.843 0.030 0.175 0.116 0.101 0.172 0.259 0.662 0.608 0.513 
Day 5 0.073 0.001 0.000 0.002 0.000 0.000 0.131 0.000 0.120 0.000 0.000 
Day 8 0.122 0.000 0.000 0.008 0.000 0.000 0.000 0.000 0.207 0.000 0.000 
Day 12 0.113 0.000 0.000 0.071 0.000 0.000 0.000 0.000 0.756 0.000 0.000 
Day 15 0.090 0.000 0.000 0.081 0.000 0.000 0.000 0.000 0.874 0.000 0.000 
Day 19 0.215 0.000 0.000 0.352 0.000 0.000 0.000 0.000 0.756 0.000 0.000 
Day 22 0.342 0.000 0.000 0.997 0.000 0.000 0.000 0.000 0.325 0.000 0.000 
Day 26 0.195 0.000 0.000 0.906 0.000 0.000 0.012 0.000 0.158 0.000 0.000 
Day 29 0.051 0.000 0.000 0.903 0.000 0.000 0.681 0.003 0.043 0.010 0.000 
CD CE CF CG DE DF DG EF EG FG 
Dayl 0.017 0.124 0.074 0.065 0.606 0.561 0.703 0.995 0.878 0.868 
Day 5 0.000 0.772 0.006 0.000 0.004 0.293 0.552 0.039 0.001 0.109 
Day 8 0.000 0.018 0.000 0.000 0.000 0.299 0.066 0.000 0.000 0.005 
Day 12 0.000 0.000 0.000 0.000 0.000 0.279 0.008 0.000 0.000 0.000 
Day 15 0.000 0.000 0.000 0.000 0.000 0.177 0.000 0.000 0.000 0.000 
Day 19 0.000 0.000 0.000 0.000 0.000 0.225 0.000 0.000 0.000 0.000 
Day 22 0.000 0.000 0.000 0.000 0.000 0.497 0.000 0.000 0.000 0.000 
Day 26 0.000 0.000 0.000 0.000 0.000 0.656 0.000 0.000 0.000 0.000 
Day 29 0.002 0.000 0.008 0.000 0.000 0.750 0.065 0.000 0.000 0.036 
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APPENDIX II 
FLOW CYTOMETRY RAW DATA 
All data presented here are quadrant and histogram readouts from CellQuest software 
used to analyze output from the Beckton Dickson FACSCalibur flow cytometer. Sample 
ID's represent the size or treatment group. Each data set begins with 'Unstained', 'PI 
only', and 'AnnexinV only'. These represent initial calibration samples that were either 
given no stain, or stained only with PI or Annexin V respectively. All other samples 
were stained with both dyes and histograms are given for both separately. All treatment 
samples were labeled by a letter: control (A), AlPcS2a dark control (B), 0.1 (J.g/mL 
bleomycin (C), 0.25 [ig/mL bleomycin (D), 1.5 J/cm2 PDT with 1 ^ig/mL AlPcS2a (E), 
PCI with 1.5 J/cm2 PDT and 0.1 ng/mL bleomycin (F), PCI with 1.5 J/cm2 PDT and 
0.25 ng/mL (G), PCI with 2.0 J/cm2 PDT and 0.25 ng/mL bleomycin (H), PDT with 2.0 
J/cm2 (I). 
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